VII. Literaturverzeichnis

1. Adam PAJ, Schwartz R. Diagnosis and treatment: should oral hypoglycemic agents be used in pediatric and pregnant patients? Pediatrics 1968; 42:819-823
2. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 1998; 21(suppl 1):S60-S61
3. Arbeitsgemeinschaft Diabetes und Schwangerschaft der Deutschen Diabetes-Gesellschaft. Empfehlungen zu Diagnostik und Therapie des Gestationsdiabetes (GDM). Frauenarzt 2001; 42:891-899
4. Baeder C, Sakaguchi T. Teratologische Untersuchungen mit HB 419. Arzneimittel-Forsch 1969; 19(Suppl 1):1419-1420
5. Bailey CJ, Nattrass M. Treatment - metformin. Clin Endocr Metab 1988; 2:455-476
6. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-772
7. Bailey CJ. Metformin - an update. Gen Pharmac 1993; 24:1299-1309
8. Batukan C, Baysal B. Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2001; 265:124-127
9. Belisle RJ, Long SY. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality. Teratology 1976; 13:65-70
10. Bertuglia S, Coppini G, Colantuoni A. Effects of metformin on arterial vasomotion in normal and diabetic Syrian hamsters. Diabète Metab 1988; 14:554-559
11. Bisisio E, Galli-Kienle M, Galli G, Ciconali M, Negri A, Sessa A, Morosati S, Sirtori CR. Defective hydroxylation of phenformin as a determinant of drug toxicity. Diabetes 1981; 30:644-649
12. Boyd RDH, Haworth C, Stacey TE, Ward RHT. Permeability of the sheep placenta to unmetabolized polar non-electrolytes. J Physiol 1976; 256:617-634
13. Brandes JM, Travoloni N, Potter JB, Sarkozi L, Shepard MD, Berk PD. A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, insulin, and antipyrine. Am J Obstet Gynecol 1983; 146:800-806
14. Briese V, Stiete H, Stiete S. Gestationsdiabetes - Perinataler Hyperinsulinismus und postnatale Entwicklungsstörungen. Zentralbl Gynakol 1997; 119:324-330

15. Caldera R. Carbutamide et malformations chez l'enfant. Ann Pédiatr 1970; 17:432-436
16. Campbell GD. Some observations upon 4000 African and Asian diabetics collected in Durban between 1958 and 1963. E Afr Med J 1963; 5:267
17. Campbell IW. Metformin and glyburide: comparative risks. Br Med J 1984; 289:289
18. Chen C. Troglitazone: an antidiabetic agent. Am J Health-Syst Pharm 1998; 55:905-925
19. Coetzee EJ, Jackson WPU. Diabetes newly diagnosed during pregnancy: a 4-year study at Groote Schuur Hospital. S Afr Med J 1979; 56:467-475
20. Coetzee EJ, Jackson WPU. Metformin in the management of pregnant insulin-independent diabetics. Diabetologia 1979; 16:241-245
21. Coetzee EJ, Jackson WPU. Pregnancy in established non-insulin-dependent diabetics. S Afr Med J 1980; 58:795-802
22. Coetzee EJ, Jackson WPU. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65:635-637
23. Coetzee EJ, Jackson WPU. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1986; 1:281-287
24. Coetzee EJ, Jackson WPU. Oral hypoglycemic agents in the treatment of gestational diabetes. In Jovanovic-Peterson L (ed): Controversies in Diabetes and Pregnancy. New York, Springer-Verlag, 1988, pp 57-76
25. Cohen Y, Costerousse O. Etude expérimentale du métabolisme du diméthylbiguanide marqué au carbone-14. 4° Congr Fed Intern Diab, Genève 1961. Med Hyg 1961; 1:745-748
26. Constam GR, Berger W. Behandlung des Diabetes mellitus mit oral wirksamen blutzuckersenkenden Medikamenten. Dtsch med Wschr 1967; 92:2278-2280
27. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-549
28. DeMeyer R. Teratogenic effects of sulfonylurea derivates 2-deoxyglucose and sodium fluoro-acetate in the rats. Proceedings of the 4° Congr Intern Diab Fed, Genève 1961, p 401
29. Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994; 49:260-266

30. Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glukose uptake and glycogen metabolism within Xenopus oocytes. Diabetologia 1998; 41:2-8
31. Diabetes and pregnancy. ACOG technical bulletin. No. 200 (replaces no. 92). Washington, D.C.: American College of Obstetricians and Gynecologists, December 1994:359-366
32. Dolger H, Bookman JJ, Nechemias C. Tolbutamide in pregnancy and diabetes. J Mt Sinai Hosp NY 1969; 36:471-474
33. Douglas CP, Richards R. Use of chlorpropamide in the treatment of diabetes in pregnancy. Diabetes 1967; 16:60-61
34. Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburid occurs across the human placenta. Am J Obstet Gynecol 1991; 165:807-812
35. Elliott BD, Schenker S, Langer O, et al. Oral hypoglycemic agents: Profound variation exists in their rate of human placental transfer. Proceedings of the 12th Annual Meeting of the Society of Perinatal Obstetricians, Orlando, FL, February 1992
36. Elliott BD, Bynum D, Langer O. Glyburide does not cross the diabetic placenta in significant amounts. Proceedings of the 13th Annual Meeting of the Society of Perinatal Obstetricians, San Francisco, CA, February 1993
37. Elliott BD, Bynum D, Langer O. Maternal hyperglycemia does not alter in-vitro placental transfer of the oral hypoglycemic agent glyburide. Proceedings of the 13th Annual Meeting of the Society of Perinatal Obstetricians, San Francisco, CA, February 1993
38. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of the oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 1994; 171:653-660
39. Elliott BD, Langer O, Schuessling F. Human placental glucose uptake and transport are not altered by the oral hypoglycemic agent metformin. Am J Obstet Gynecol 1997; 176:527-530
40. Freinkel N. Discussion. In Camerini-Davalos RA, Cole HS (eds): Early Diabetes in Early Life. New York, San Francisco, London, Academic Press, 1975, pp 517-518

41. Freinkel N, Metzger BE, Phelps RL, et al. Gestational diabetes mellitus: Heterogeneity of maternal age, weight, insulin secretion, HLA antigens, and islet cell antibodies and the impact of maternal metabolism on pancreatic ß-cell and somatic development in the offspring. Diabetes 1985; 34:1-7
42. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46-52
43. Goodman A. Efficacy and safety of metformin in NIDDM: results of a multicenter trial. Diabetes 1993; 42(suppl 1):Abs178
44. Greene MF, Hare JW, Clorerty JP, Benacerraf BR, Soeldner JS. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989; 39:225-231
45. Gregorio F, Ambrosi F, Marchetti P, Cristallini S, Navalesi R, Brunetti P, Filipponi P. Low-dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations. Acta Diabetol Lat 1990; 27:139-155
46. Hay WW. Placental control of fetal metabolism. In Sharp F, Fraser RB, Milner RDG (eds): Fetal growth. Heidelberg, Springer, 1989, p 33
47. Hay WW. Metabolic interrelationships of placenta and fetus. Placenta 1995; 16:19-30
48. Heisig N. Zur Problematik der oralen Diabetestherapie in der Schwangerschaft. Med Klin 1971; 66:445-448
49. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17:507-511
50. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 1979; 5:233-245
51. Herold G, Deuss U. Diabetes mellitus. In Herold G (Hrsg): Innere Medizin. Köln, 1995, S. 544-566
52. Hopp H, Leis R. Diabetes und Schwangerschaft. Z Klin Med 1990; 45:2089
53. Hopp H, Vollert W, Ragosch V, Pritze W, Ebert A, Entezami M, Weitzel H. Vermeidung kindlicher Risiken durch ein generelles Gestationsdiabetes-Screening, intensive Diagnostik und konsequente Therapie. Geburtsh Frauenheilk 1995; 55:28-31

54. Hopp H, Vollert W, Ragosch V, Novak A, Weitzel H, Glöckner E, Besch W. Indication and results of insulin therapy for gestational diabetes mellitus. J Perinat Med 1996; 24:521-530

55. Hopp H. Gestationsdiabetes: Auswirkungen und Konsequenzen. Hebamme 2000; 3:155-158

56. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992; 131:1165-1173

57. Iwamoto Y, Kuzuya T, Fujita N, et al. Effect of CS-045 (troglitazone) in patients with NIDDM. In Sakamoto N, Alberti KGMM, Hotta N (eds): Pathogenesis and treatment of NIDDM and its related problems. New York, Elsevier Science B.V., 1994, pp 313-317

58. Jackson WPU, Campbell GD, Notelovitz M, Blumsohn D. Tolbutamide and chlorpropamide during pregnancy in human diabetics. Diabetes 1962; 11(suppl):98-103

59. Jackson RA, Hawa MI, Jaspan JV, Sim BM, Disilvio L, Featherbe D, Kurtz AB. Mechanism of metformin action in non-insulin dependent diabetes. Diabetes 1987; 36:632-640

60. Jansson T, Wennergren M, Illsley NP. Glucose transporter protein expression in human placenta throughout gestation and in intrauterine growth retardation. J Clin Endocrinol Metab 1993; 77:1554-1562

61. Jensen DM, Sørensen B, Feilberg-Jørgensen N, Westergaard JG, Beck-Nielsen H. Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profile. Diabet Med 2000; 17:281-286

62. Kainer F, Weiss PAM, Hüttner U, Haas J, Reles M. Levels of amniotic fluid insulin and profiles of maternal blood glucose in pregnant women with diabetes type-I. Early Human Development 1997; 49:97-105

63. Kemball ML, McIver C, Milner RD, et al. Neonatal hypoglycemia in infants of diabetic mothers given sulfonylurea drugs in pregnancy. Arch Dis Child 1970; 45:696-701

64. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991; 265:731-736
65. Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. Am J Health-Syst Pharm 1997; 54:893-903
66. Kuhl C. Insulin secretion and insulin resistance in pregnancy and GDM implications for diagnosis and management. Diabetes 1991; 40(suppl 2):18-24
67. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces blood pressure and metabolic risk factors. J Int Med 1991; 229:181-187
68. Langer O. Management of gestational diabetes. Clinics in Perinatology 1993; 20:603-617
69. Langer O, Brustman L, Anyaegbuman A. The significance of one abnormal glucose test value on adverse outcome in pregnancy. Am J Obstet Gynecol 1995; 175:758-763
70. Langer O, Conway DL, Berkus MD, Xenakis EMJ, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343:1134-1138
71. Lazarus SS, Volk BW. Absence of teratogenic effect of tolbutamide in rabbits. J Clin Endocr 1963; 23:597
72. Lucis OJ. The status of metformin in Canada. Can Med Ass J 1983; 128:24-26
73. Malek A, Miller RK, Mattison DR, et al. 31P Spectroscopy of dually perfused human placenta. Trophoblast Res 5
74. Metzger BE, Coustan DR, Organizing Committee. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes. Diabetes Care 1998; 21(suppl 2):B161-B167
75. Montanari G, Bondioli A, Rizzato G, Puttini M, Temoli E, Mussoni L, Mannucci L, Pazzucconi F, Sirtori CR. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol Res 1992; 25:63-73
76. Moss JM. Treatment of pregnant diabetics with oral hypoglycemic drugs. Sth Med J 1966; 59:695-697
77. Mulford MI, Jovanovic-Peterson L, Peterson CM. Alternative therapies for the management of gestational diabetes. Clinics in Perinatology 1993; 20:619-634

78. Notelovitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971; 45:226-229
79. Notelovitz M. Oral hypoglycaemic therapy in diabetic pregnancies. Lancet 1974; ii:902-903
80. O'Sullivan J. The Boston Gestational Diabetes Studies: Review and Perspectives. In Sutherland H, Stowers J, Pearson D (eds): Carbohydrate Metabolism in Pregnancy and the Newborn IV. London, Springer, 1989, pp 287-294
81. Pedersen J, Molsted-Pedersen L. Oral "antidiabetic" compounds in pregnancy. In Davalos RC, Cole HS (eds): Early Diabetes in Early Life. New York, San Francisco, London, Academic Press Inc., 1975, pp 487-494
82. Pedersen J. The pregnant diabetic and her newborn, ed 2. Munksgaard, Copenhagen, Baltimore, Williams and Wilkens, 1977, pp 22-45
83. Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 1991; 338:866-869
84. Plagemann A, Harder T, Kohlhoff R, Rohde W, Dörner G. Glucose tolerance and insulin secretion in children of mothers with pregestational IDDM or gestational diabetes. Diabetologia 1997; 40:1094-1100
85. Rambert P, Bernard S, Thervet F. Thérapeutique orale du diabète. Presse méd 1969; 77:1117
86. Reid JA, Russel G. Qualitative assessment of children of known-gestational diabetic mothers. In Sutherland HW, Stowers JM (eds): Carbohydrate Metabolism in Pregnancy and the Newborn. Berlin, Heidelberg, New-York, Springer-Verlag, 1979, pp 462-477
87. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45:1661-1669
88. Schäfer-Graf UM, Dupak J, Vogel M, Dudenhausen JW, Kjos SL, Buchanan TA, Vetter K. Hyperinsulinism, neonatal obesity and placental immaturity in infants born to women with one abnormal glucose tolerance test value. J Perinat Med 1998; 26:27-36
89. Schenker S, Johnson R, Hays S, Ganeshappa R, Henderson G. Effects of nicotine and nicotine/ethanol on human placental amino acid transfer. Alcohol 1989; 6:289-296

90. Schiff D, Aranda JV, Stern L. Neonatal thrombocytopenia and congenital malformations associated with administration of tolbutamide to the mother. J Pediatr 1970; 27:457-458
91. Schneider H. The role of the placenta in nutrition of the human fetus. Am J Obstet Gynecol 1991; 164:967-973
92. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacological Research 1994; 30:187-228
93. Sivan E, Feldman B, Dolitzki M, Nevo N, Dekel N, Karasik A. Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia 1995; 38:753-756
94. Smoak IW, Sadler TW. Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol 1990; 163:619-624
95. Smoak IW. Teratogenic effects of chlorpropamide in mouse embryos in vitro. Teratology 1992; 45:474 (abstract)
96. Sterne J, Lavieuville M. Recherches cliniques sur les effets des antidiabétiques oraux sur le fœtus. Presse Médicale 1963; 71:1547-1549
97. Sterne J. Klinische Rundfrage über die eventuellen teratogenen Effekte der oralen Antidiabetika bei der schwangeren zuckerkranken Frau. IV. Intern Sympos Diabetesfragen Karlsburg 1965, S. 28
98. Sterne J, Lavieuville M. Biguanides in pregnancy (Translated) Paper presented at symposium on the biguanides. Rimini, October 1968
99. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care 1990; 13:631-654
100. Stowers JM, Sutherland HW. The use of sulfonylureas, biguanides and insulin in pregnancy. In Sutherland HW, Stowers JM (eds): Carbohydrate metabolism in pregnancy and the newborn. Edinburgh, Churchill & Livingstone, 1975, pp 205-220
101. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20:925-928
102. Sutherland HW, Stowers JM, Cormack JD, Bewsher PD. Evaluation of chlorpropamide in chemical diabetes diagnosed during pregnancy. BMJ 1973; 3:9-13

103. Suzuki N, Oka Y, Lir J-L, et al. Protein contents of GLUT-1 and GLUT-3 of human placental tissue at delivery of diabetic mothers do not relate to neonatal birth weight [Abstract]. Proc of the 1st Int Symp on Diabetes and Pregnancy in the 90's, 1992; p 104
104. Tuchmann-Duplessis H. Drug effects on the fetus. A survey of the mechanisms and effects of drugs on embryogenesis and fetogenesis. Sydney: ADIS, 1975:198-208
105. Vetter C. Der Fortschritt ist eine Schnecke. Deutsches Ärzteblatt 2001; 98:1864-1865
106. Wegner B. Diabetes mellitus - Moderne Behandlungsstrategien. Brandenburgisches Ärzteblatt 2002; 12:12-15
107. Weiss PAM. Gestational diabetes: a survey and the Graz approach to diagnosis and therapy. In Weiss PAM, Coustan DR (eds): Gestational diabetes. Vienna, New York, Springer, 1988
108. Weiss PAM, Hofmann HMH. Gestationsdiabetes. In Bolte A, Wolff F (Hrsg): Hochrisikoschwangerschaft. Darmstadt, Steinkopff, 1989.
109. Weiss PAM, Walcher W, Scholz HS. Der vernachlässigte Gestationsdiabetes: Risiken und Folgen. Geburtsh u Frauenheilk 1999; 59:535-544
110. Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs 1995; 4:1299-1309
111. Wilcock C, Wyre N, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmac 1991; 43:442-444
112. Willis DM, O'Grady JP, Faber JJ, Thornburg KL. Diffusion permeability of cyanocobalamin in human placenta. Am J Physiol 1986; 250:R459-464
113. Young MPA, Schneider H. Metabolic integrity of the isolated perfused lobule of human placenta. Placenta 1984; 5:95-104